Authors:
SHAPIRO AD
WHITE GC
KIM HC
LUSHER JM
BERGMAN GE
Citation: Ad. Shapiro et al., EFFICACY AND SAFETY OF MONOCLONAL-ANTIBODY PURIFIED FACTOR-IX CONCENTRATE IN HEMOPHILIA-B PATIENTS UNDERGOING SURGICAL-PROCEDURES, Haemophilia, 3(4), 1997, pp. 247-253
Authors:
DAVIS HM
NASH DW
CLYMER MD
FRIGO ML
BERGMAN GE
Citation: Hm. Davis et al., LACK OF IMMUNE-RESPONSE TO MOUSE IGC IN PREVIOUSLY UNTREATED HEMOPHILIA-A AND HEMOPHILIA-B PATIENTS TREATED WITH MONOCLONAL-ANTIBODY PURIFIED FACTOR-VIII AND FACTOR-IX PREPARATIONS, Haemophilia, 3(2), 1997, pp. 102-107
Citation: E. Kurczynski et al., CONTINUOUS-INFUSION OF MONOCLONAL-ANTIBODY PURIFIED FACTOR-IX IN HEMOPHILIA-B SURGICAL, TRAUMA, OR SEVERE SPONTANEOUS HEMORRHAGE PATIENTS, Thrombosis and haemostasis, 1997, pp. 214-214
Citation: A. Shapiro et Ge. Bergman, MONOCLONAL-ANTIBODY PURIFIED FACTOR-IX DOSING TRENDS GIVEN FOR PREVIOUSLY UNTREATED PATIENTS (PUPS), Thrombosis and haemostasis, 1997, pp. 216-216
Citation: C. Cornell et al., SAFETY AND EFFICACY OF STIMATE(R) (DESMOPRESSIN ACETATE, 1.5 MG ML) NASAL SPRAY IN PATIENTS WITH MILD HEMOPHILIA-A/, Thrombosis and haemostasis, 1997, pp. 998-998
Citation: N. Kobrinsky et Ge. Bergman, SAFETY AND EFFICACY OF STIMATE(R) (DESMOPRESSIN ACETATE, 1.5 MG ML) NASAL SPRAY IN PATIENTS WHO ARE HEMOPHILIA-A CARRIERS/, Thrombosis and haemostasis, 1997, pp. 999-999
Citation: M. Pai et al., HAEMATE(R) DOSING TRENDS AMONG 97 CANADIAN VON-WILLEBRAND-DISEASE (VWD) PATIENTS, Thrombosis and haemostasis, 1997, pp. 2098-2098
Authors:
BLANCHETTE V
ISRAELS SJ
AKABUTU J
BERGMAN GE
Citation: V. Blanchette et al., REPORT OF THE EFFICACY AND SAFETY OF HAEMATE(R)-P IN CANADIAN VON-WILLEBRAND-DISEASE (VWD) PATIENTS, Thrombosis and haemostasis, 1997, pp. 2100-2100
Authors:
PHILIPP CS
MAUSERBUNSCHOTEN E
SAVIDGE G
BERGMAN GE
Citation: Cs. Philipp et al., VIRAL SAFETY OF MONOCLONAL-ANTIBODY PURIFIED FACTOR-VIII - RESULTS FROM PREVIOUSLY UNTREATED PATIENTS (PUPS), Thrombosis and haemostasis, 1997, pp. 2647-2647
Citation: Jc. Gill et al., COMPARISON OF INTRAVENOUS (IV) AND INTRANASAL (IN) DESMOPRESSIN ACETATE (DDAVP) IN PATIENTS WEIGHING LESS-THAN-OR-EQUAL-TO-50 KG WITH MILD HEMOPHILIA-A (HA) OR MILD-TO-MODERATE VON-WILLENBRAND-DISEASE (VWD, TYPE-1), Thrombosis and haemostasis, 1997, pp. 2840-2840
Citation: D. Becton et al., SAFETY AND EFFICACY OF STIMATE(R) (DESMOPRESSIN ACETATE, 1.5 MG ML) NASAL SPRAY IN PATIENTS WITH MILD-TO-MODERATE VON-WILLEBRAND-DISEASE (VWD)/, Thrombosis and haemostasis, 1997, pp. 2842-2842
Authors:
SHAPIRO AD
RAGNI MV
LUSHER JM
CULBERT S
KOERPER MA
BERGMAN GE
HANNAN MM
Citation: Ad. Shapiro et al., SAFETY AND EFFICACY OF MONOCLONAL-ANTIBODY PURIFIED FACTOR-IX CONCENTRATE IN PREVIOUSLY UNTREATED PATIENTS WITH HEMOPHILIA-B, Thrombosis and haemostasis, 75(1), 1996, pp. 30-35
Citation: Mm. Hannan et al., EVALUATION OF THE SAFETY AND EFFICACY OF STIMATE(R) (DESMOPRESSIN ACETATE, 1.5 MG ML) NASAL SPRAY UTILIZING INTERACTIVE VOICE RESPONSE (IVE) TECHNOLOGY/, Blood, 88(10), 1996, pp. 3022-3022
Authors:
CHANDRA S
JEROME CP
COWDEN D
WEEKS R
FLANIGAN E
FELDMAN F
BERGMAN GE
LIN C
Citation: S. Chandra et al., THE REMOVAL OF HEPATITIS-C VIRAL GENOMIC MATERIAL DURING THE MANUFACTURING PROCESS OF INTRAVENOUS IMMUNE GLOBULIN, Blood, 88(10), 1996, pp. 3087-3087
Citation: Mm. Hannan et al., EVALUATION OF THE SAFETY AND EFFICACY OF STIMATE(R) (DESMOPRESSIN ACETATE, 1.5 MG ML) NASAL SPRAY IN A PHASE 4 MULTICENTER TRIAL/, Blood, 88(10), 1996, pp. 1311-1311
Citation: Jc. Gill et al., EVALUATION OF STIMATE(R) (DESMOPRESSIN ACETATE) NASAL SPRAY, 1.5 MG ML IN PATIENTS WEIGHING LESS-THAN-OR-EQUAL-TO-50 KG WITH MILD HEMOPHILIA-A OR MILD-TO-MODERATE VON-WILLEBRAND DISEASE (TYPE-1)/, Blood, 88(10), 1996, pp. 1754-1754
Authors:
KURCZYNSKI E
LUSHER JM
PITEL P
SHAPIRO AD
BERGMAN GE
Citation: E. Kurczynski et al., SAFETY AND EFFICACY OF MONOCLONAL ANTIBODY-PURIFIED FACTOR-IX CONCENTRATE FOR MANAGEMENT OF BLEEDING AND SURGICAL PROPHYLAXIS IN PREVIOUSLYTREATED CHILDREN WITH HEMOPHILIA-B, International journal of pediatric hematology/oncology, 2(3), 1995, pp. 211-216
Authors:
WARRIER I
KASPER CK
WHITE GC
SHAPIRO AD
BERGMAN GE
Citation: I. Warrier et al., SAFETY OF HIGH-DOSES OF A MONOCLONAL ANTIBODY-PURIFIED FACTOR-IX CONCENTRATE, American journal of hematology, 49(1), 1995, pp. 92-94
Citation: A. Shapiro et Ge. Bergman, SAFETY OF MONOCLONAL ANTIBODY-PURIFIED FACTOR-IX IN PREVIOUSLY UNTREATED PATIENTS (PUPS) WITH HEMOPHILIA-B, Thrombosis and haemostasis, 73(6), 1995, pp. 1021-1021
Citation: A. Shapiro et al., SAFETY AND EFFICACY OF MONOCLONAL-ANTIBODY (MAB)-PURIFIED FACTOR-IX FOR PROPHYLAXIS AGAINST BLEEDING IN HEMOPHILIA-B PATIENTS UNDERGOING SURGICAL-PROCEDURES, Thrombosis and haemostasis, 73(6), 1995, pp. 1022-1022
Authors:
WHITE GC
SHAPIRO AD
KURCZYNSKI EM
KIM HC
BERGMAN GE
BENJAMIN L
BROOKS P
CORNELL NJ
CZAPEK E
DAVIS RT
DIMICHELE D
DJULBEGOVIC B
GILL JC
GOLDSMITH J
GORDON ME
GREEN D
GREENBERG S
GRIBBLE J
HILGARTNER M
HODDER F
HUTTER JJ
JANCO R
KASPER C
KESSLER C
LUSHER J
MARTINOWITZ U
OPENSHAW TH
PHILLIPS M
PITEL P
POTOLSKY A
PRESTON FE
RAUSEN A
SAVIDGE G
SEXAUER C
SHURAFA M
SMITH G
SWEENEY J
TELFORD M
WILDE J
WILSON W
Citation: Gc. White et al., VARIABILITY OF IN-VIVO RECOVERY OF FACTOR-IX AFTER INFUSION OF MONOCLONAL-ANTIBODY PURIFIED FACTOR-IX CONCENTRATES IN PATIENTS WITH HEMOPHILIA-B, Thrombosis and haemostasis, 73(5), 1995, pp. 779-784
Citation: B. Djulbegovic et al., CONCOMITANT TREATMENT WITH FACTOR-IX CONCENTRATES AND ANTIFIBRINOLYTICS IN HEMOPHILIA-B, Acta haematologica, 94, 1995, pp. 43-48